« Return to News | Drug Sponsors

Wellcome Trust awards Phagenesis $1.5 million for dysphagia treatment

Tuesday, May 22, 2012 10:02 AM

Phagenesis, a U.K. company focused on dysphagia (the inability to swallow), has been awarded $1.5 million from the Wellcome Trust to extend the scope of its dysphagia treatment device, from hospitals into the community.

Phagenesis’ technology is designed to treat patients who are dysphagic following a stroke. Currently, there is no generally accepted treatment for the condition and patients typically have to be fed puréed food and thickened liquids or be fed through a tube, which can severely limit their quality of life.

Phagenesis has developed the world’s first clinically-proven device to treat dysphagia in stroke patients in the first few weeks while they are hospitalised. With the help of the Wellcome Trust, Phagenesis is now developing and testing a new version of its device to treat patients suffering from long-term dysphagia.

“Our technology can make a significant difference to patients in the hospital who have this difficult-to-treat condition,” said Daniel Green, CEO of Phagenesis. “We believe this benefit can be extended more widely to people outside the hospital setting. We are delighted to have the support of the Wellcome Trust to adapt our technology and reach these patients and improve their quality of life.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.